Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partners with Atascosa Explor

18 Jun 2008 07:00

RNS Number : 9543W
ViaLogy PLC
18 June 2008
 



ViaLogy partners with Texas exploration group Atascosa to analyse onshore oil fields

Pasadena, 18 June:  ViaLogy PLC (LSE:VIY)a leading innovator of real-time network-centric signal processing platforms, announces that it has entered into an agreement with a Texas-based oil and gas exploration and production company, Atascosa Exploration LLC,  of San Antonio, to use ViaLogy's  unique technology, QuantumRD™, to analyse seismic data for more accurate definition of the extent and density of underground oil reservoirs prior to the commencement of drilling. The data analysis on three prospective Texas-based well sites will begin immediately. Complete results will be delivered by ViaLogy to Atascosa within three weeks, and exploratory drillinto prove the technology will commence soon afterwards.

The problems of predicting oil traps from coarse seismic data analysis have plagued the oil and gas industry for decades. Pinpoint accuracy is essentialPredictions that are just a few feet out can waste millions of dollars.

QuantumRD applies ViaLogy's patented and proven Quantum Resonance Interferometry (QRI™) technology to analyse coarse 2D and 3D seismic signals and extract more detailed and accurate information than has hitherto been possibleFor the first three pilot wells ViaLogy and Atascosa have reached a non-operating interest participation arrangement, which is based on production in excess of their oil trap estimates prior to the QuantumRD analysis. Assuming that the analysis proves successful the two companies have agreed to form a joint venture company or other business arrangement for the commercialisation of Quantum RD within the United States.

Atascosa CEO, John D. Mullins, said, "We are delighted that Atascosa can take the lead in bringing ViaLogy's technology to market. A successful pilot should result in the widespread use of QuantumRD throughout the industry."

 ViaLogy CEO, Robert W. Dean, said, "QuantumRD should increase the accuracy of existing and future seismic petroleum data reduce false positives about where to drill, and have a significant impact on the oil exploration industry. It should also offer ViaLogy opportunity to expand its sales in an adjacent market. Atascosa is the ideal partner for us."

Mr. Dean pointed out that, if the pilot analysis proves successful, the potential for QuantumRD™ iextensive According to Energy Information Administration (EIA)'s 2006 Annual Report, US had over 21 billion barrels of proven oil reserves. Most of the newer discoveries are in smaller fields. However, the number of newer oilfield discoveries has declined from 1400 in 2001 to 30 by 2006Just over 40 new reservoirs were discovered in known US fields in 2006 based on EIA released numbers.

"Due to the high cost of oil today, producers can now afford to bring on line reserves that were previously passed over because of production rate or quantity or quality of reservoir. QuantumRD shines in this environment because it allows a clear definition of reservoir size and shape. Based on EIA released data, wells in the US are now averaging over 5700 feet in depth. As the cost to drill wells between 5,000 and 12,000 feet is now approximately $1.5 million to $4 million dollars, making an accurate prediction of reservoir characteristics is even more of an economic necessity. ViaLogy's preferred business model is ainterpretation fee and overriding royalty interest (ORRI).  Our ability to accurately predict reservoir size and quality should become a required part of the search for hydrocarbons here and abroad."

  For Further Information please contact

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656).

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications

Samantha Robbins / Anna Dunkin +44 (0) 20-7822-0200

 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFDLLFVQBXBBD
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.